Investors

Latest Financial Results

Q1 2024

Quarter Ended Mar 31, 2024

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2023

Company Overview

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) is a pre-clinical-stage pharmaceutical development company with two neuroscientific programs targeting a broad range of neurologic and neuropsychiatric disorders. Our novel oral pharmaceutical marijuana, MIRA-55, is currently under investigation for treating adult patients suffering from neuropathic pain, anxiety and cognitive decline, often associated with early-stage dementia. MIRA-55, if approved by the FDA, could mark a significant advancement in addressing various neuropsychiatric, inflammatory, and neurologic diseases and disorders, by being the first treatment under development to restore cognition while simultaneously ameliorating anxiety. We have an exclusive licensing agreement for Ketamir-2 (“Ketamir”), a unique, patent pending novel oral ketamine analog under investigation to potentially deliver ultra-rapid antidepressant effects for patients who have not had a meaningful response to conventional treatments, providing new hope for individuals battling treatment-resistant depression (TRD) and major depressive disorder with suicidal ideation (MDSI). The U.S. Drug Enforcement Administration (DEA)'s scientific review of Ketamir concluded that it would not be considered a controlled substance or listed chemical under the Controlled Substances Act (CSA) and its governing regulations. MIRA-55 is unscheduled.

Stock Snapshot

IR Contacts

Company

MIRA Pharmaceuticals, Inc.
1200 Brickell Ave.
Suite 1950 #1183
Miami, FL 33133
United States
T: 786-432-9792
info@mirapharma.com

Investor Relations

MIRA Pharmaceuticals, Inc.
T: 786-432-9792
info@mirapharma.com

Transfer Agent

Equiniti
48 Wall Street, 23rd FL.
New York, NY 10005
T: US 800-401-1957<br>Canada/US Virgin Islands 800-468-9716<br>Other <a href="https://www.shareowneronline.com/media/1179/sol-classic-international-access-codes.pdf" target="_blank" rel="noopener">International Access Codes</a>
Rohan.bickram@equiniti.com